Immunotherapy vs. Chemotherapy as Second-line Treatment for NSCLC
March 1st 2023A real-world evidence study shows an advantage in median overall survival among non-small cell lung cancer patients who were treated with second-line immunotherapy compared to those treated with chemotherapy. Multivariable analysis showed healthcare resource utilization was comparable.
Read More